Figure 2.
Effects of imatinib and sorafenib on the expression of ACTA2 and collagens. Mice were challenged with Concanavalin A for four weeks and then treated with either imatinib, sorafenib, a combination of imatinib and sorafenib, or vehicle for three weeks. At the end of the treatment period, mice were euthanized and their livers were collected for the determination of alpha-SMA (ACTA2) (A), COL1A1 (B), COL1A2 (C), and COL3A1 (D) via real-time PCR. * p < 0.05; ** p < 0.01; *** p < 0.001.